Trial Profile
A Double-masked, Placebo-controlled, Dose-escalation Study and Double-masked, Two-sequence, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-9054 in Patients With Ocular Hypertension or Mild Open-Angle Glaucoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Jun 2017
Price :
$35
*
At a glance
- Drugs Sepetaprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 12 Jun 2014 New trial record